Bioceres Lenders Claim Default, And Dilution Risks Are Higher Than Ever

Group 1 - Bioceres (BIOX) reported its 1Q26 results (3Q25 calendar), indicating ongoing challenges in revenue across all markets [1] - The company experienced improved gross margins, which somewhat offset the revenue challenges [1] - Significant reductions in operating expenses (OpEx) contributed to enhanced profitability [1]